ResMed beat expectations by reporting Q4 earnings of 73 cents per share on quarterly of revenue of $530.40 million. During the same period last year, the firm earned 69 cents per share. This represents a 16.7% increase in revenue from the same period last year.
The street had estimated earnings of 70 cents a share on quarterly revenue of $518.60 million.
You're not a member! Trial today
These earnings and revenue figures represent a return on equity of 23.10% and a net margin of 17.87%
We started buying ResMed last week, ahead of the earnings release. We’re now up 6% from our entry level and will look at add covered call options to further enhance the return.
